Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs)

被引：0
|
作者：
H. U. Schorlemmer
R. Kurrle
R. R. Bartlett
机构：
[1] Research Laboratories Hoechst Marion Roussell (HMR),
[2] TA Rheumatology/Immunology,undefined
[3] c/o Behringwerke AG,undefined
[4] P.O. Box 1140,undefined
[5] D-35001 Marburg,undefined
[6] Germany,undefined
[7] Fax +49 6421 39 46 63,undefined
[8] Werk Kalle-Albert,undefined
[9] D-65174 Wiesbaden,undefined
[10] Germany,undefined
来源：
Inflammation Research | 1997年 / 46卷 / Suppl 2期
关键词：
Host Disease;
D O I：
10.1007/s000110050160
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：165 / 166
页数：1
相关论文
共 50 条
  • [41] Predicting risk of infection and graft vs. host disease (GvHD), and response to immonosuppression (ISP) in allogeneic hematopoietic stem cell transplant (HSCT) patients (pts) using the Cylex®ImmuKnow® assay:: A pilot study.
    Anaissie, Elias J.
    Diaz, Jose A.
    Grazziutti, Monica L.
    Miceli, Marisa H.
    Fox-Cottler, Mchele
    Barlogie, Bart
    BLOOD, 2006, 108 (11) : 423B - 423B
  • [42] Evidence that cotransplantation of purified human bone marrow mesenchymal progenitor cells supports engraftment of human T and B lymphocytes in SCID mice, minimizes graft vs. host disease (GVHD), and prolongs their survival.
    Seshi, B
    Kumar, S
    King, D
    BLOOD, 2001, 98 (11) : 653A - 653A
  • [43] A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD) Potently Suppresses Human Mixed Lymphocyte Reactions and Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD)
    Dillon, Stacey R.
    Lewis, Katherine E.
    Swanson, Ryan
    Evans, Lawrence S.
    Kornacker, Michael G.
    Levin, Steven D.
    Wolfson, Martin F.
    Rickel, Erika
    Bort, Susan J.
    Moss, Aaron M.
    Seaberg, Michelle A.
    Bhandari, Janhavi
    MacNeil, Sean
    Hoover, Joe
    Rixon, Mark W.
    Peng, Stanford L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S187 - S188
  • [44] Total Marrow and Lymphoid Irradiation to 20 Gy Combined With Post-Transplant Cyclophosphamide Graft vs. Host Disease (GvHD) Prophylaxis is Associated With Low Non-Relapse Mortality Rates and Favorable GvHD-Free/Relapse-Free Survival in AML
    Stein, A.
    Al Malki, M.
    Yang, D.
    Liu, A.
    Han, C.
    Palmer, J.
    Dandapani, S. V.
    Farol, L.
    Hui, S. K.
    Marcucci, G.
    Nakamura, R.
    Pullarkat, V.
    Rosenthal, J.
    Salhotra, A.
    Spielberger, R.
    Forman, S. J.
    Wong, J. Y. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S82 - S82
  • [45] SEVERE TRANSPLANT ASSOCIATED MICROANGIOPATHY (TAM) MAY BE LINKED TO SEVERE ORGAN INJURY IN PEDIATRIC PATIENTS TREATED WITH SIROLIMUS (SIR) AND CALCINEURIN INHIBITOR (CNI) FOR PREVENTION OR TREATMENT OF GRAFT-VS-HOST DISEASE (GVHD)
    Rosenthal, J.
    Bolotin, E.
    Pawlowska, A.
    Oliver, C.
    Forman, S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 111 - 111
  • [46] In multiple myeloma (MM) CAMPATH-1 antibodies "in the bag" reduce the early toxicity of stem cell transplantation from graft vs. host disease (GvHD) and seem to be associated with improved long term outcome.
    Novitzky, Nicolas
    Thomas, Valda
    du Toit, Cecile
    BLOOD, 2006, 108 (11) : 433B - 433B
  • [47] Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis
    Urbano-Ispizua, Alvaro
    Pavletic, Steven Z.
    Flowers, Mary E. D.
    Zhang, Mei-jie
    Carreras, Jeanette
    Smith, Sonali M.
    Maloney, David G.
    Montoto, Silvia
    Cutler, Corey S.
    Spellman, Stephen R.
    Arora, Mukta
    Saber, Wael
    BLOOD, 2013, 122 (21)
  • [48] Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non-Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease Prevention
    Khimani, Farhad
    Dean, Erin
    Rizk, Victoria
    Kim, Jongphil
    Chen, Lu
    Nishihori, Taiga
    Kharfan-Dabaja, Mohamed
    Betts, Brian
    Mishra, Asmita
    Ayala, Ernesto
    Locke, Frederick L.
    Field, Teresa
    Ochoa-Bayona, Jose Leonel
    Perez, Lia Elena
    Nieder, Michael L.
    Alsina, Melissa
    Fernandez, Hugo
    Anasetti, Claudio
    Pidala, Joseph A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S402 - S403
  • [49] Donor T cells which cannot mediate perforin dependent and FasL-dependent cytotoxicity can effect graft vs. Host reactivity following allogeneic bone marrow transplantation
    Jiang, Z
    Podack, EM
    Levy, RB
    PERIODICUM BIOLOGORUM, 1998, 100 (04) : 477 - 481
  • [50] Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd
    Pidala, Joseph
    Kim, Jongphil
    Jim, Heather
    Fernandez, Hugo F.
    Tomblyn, Marcie
    Kharfan-Dabaja, Mohamed A.
    Betts, Brian C.
    Nishihori, Taiga
    Xu, Mian
    Janssen, William E.
    Locke, Frederick L.
    Ayala, Ernesto
    Perez, Lia
    Perkins, Janelle
    Field, Teresa
    Ochoa, Leonel
    Alsina, Melissa
    Anasetti, Claudio
    BLOOD, 2011, 118 (21) : 151 - 152
12345